Literature DB >> 1488990

Additional dystrophin fragment in Becker muscular dystrophy may result from proteolytic cleavage at deletion junctions.

A H Beggs1, E P Hoffman, L M Kunkel.   

Abstract

Becker muscular dystrophy is usually caused by intragenic dystrophin gene deletions that result in production of an internally deleted protein. Previous studies have detected what appears to be a unique dystrophin degradation product that appears only in muscle biopsies from patients with Becker muscular dystrophy. This dystrophin fragment is always seen in addition to the "full-size" dystrophin of the expected size for a given gene deletion. It is only found in biopsies from patients with mutations in the deletion-prone region encompassing exons 45-53, but it does not appear to correlate with any observable phenotype at the clinical level. By correlating the size and locations of dystrophin gene deletions with the size of this degradation product, together with use of region-specific dystrophin antisera, we find that proteolytic cleavage may occur at the deletion breakpoints, perhaps due to alterations of the secondary and/or tertiary structures of the protein. This cleavage results in loss of the carboxy-terminal domains that are thought to be important for interactions between dystrophin and other membrane-bound proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1488990     DOI: 10.1002/ajmg.1320440322

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  4 in total

1.  Monoclonal antibodies against the muscle-specific N-terminus of dystrophin: characterization of dystrophin in a muscular dystrophy patient with a frameshift deletion of exons 3-7.

Authors:  T T Le; T M Nguyen; D R Love; T R Helliwell; K E Davies; G E Morris
Journal:  Am J Hum Genet       Date:  1993-07       Impact factor: 11.025

2.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

3.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

4.  Pathological evaluation of rats carrying in-frame mutations in the dystrophin gene: a new model of Becker muscular dystrophy.

Authors:  Naomi Teramoto; Hidetoshi Sugihara; Keitaro Yamanouchi; Katsuyuki Nakamura; Koichi Kimura; Tomoko Okano; Takanori Shiga; Taku Shirakawa; Masafumi Matsuo; Tetsuya Nagata; Masao Daimon; Takashi Matsuwaki; Masugi Nishihara
Journal:  Dis Model Mech       Date:  2020-09-28       Impact factor: 5.758

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.